FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287874627> ?p ?o ?g. }

• W2287874627 abstract "Abstract Outcomes for patients with childhood acute lymphoblastic leukaemia (ALL) are increasingly successful. Nevertheless, 20% of cases relapse due to failure to eradicate the disease, emphasising the need for more effective treatment. We and others have shown that multiple ALL subpopulations contain leukaemia initiating cells (LIC) that have the capacity to engraft and generate leukaemias in immune deficient mice. In addition, we have shown that some of these populations are resistant to current therapies and these cells may be responsible for disease relapse. Therefore, future therapies should be designed to target and eradicate all LIC populations. Preliminary results from our whole genome microarray analyses on bulk B-ALL cells and LIC subpopulations have indicated that certain key proteasome pathway and Hsp90 genes are similarly expressed across the LIC subpopulations. Therefore, inhibitors of these genes may be effective on all LIC subpopulations. Proteasome and heat shock protein (Hsp) 90 inhibitors are promising agents in cancer therapy. Bortezomib, a specific proteasome inhibitor, currently used in multiple myeloma, disrupts various signalling pathways leading to cell cycle arrest and apoptosis. Hsp90 is involved in the maturation and stabilisation of a wide range of oncogenic client proteins involved in survival and tumour progression. Hsp90 inhibitors, such as 17-DMAG and Celastrol have been shown to suppress B- and T-ALL cells, while sparing normal haemopoietic stem cells (HSC). 17-DMAG targets the ATP-binding domain of Hsp90 and Celastrol disrupts the Cdc37-Hsp90 complex, so when used in combination their potential to target leukaemia cells might be improved. The aim of this study was to investigate the effects of Bortezomib and the Hsp90 inhibitor combination 17-DMAG and Celastrol (Hsp90i) in childhood ALL. The viability and functional capacity of specific LIC subpopulations from 4 B-ALL cases and 5 CD34+/CD38- HSC samples following drug treatment were assessed by flow cytometry and functional assays. Cells were stained with Annexin V, 7AAD and antibodies against CD34 and CD19 (B-ALL) or CD34 and CD38 (normal cells). Following treatment with 1nM Bortezomib, the proportions of surviving bulk ALL cells, CD34+/CD19+, CD34+/CD19- and CD34-/CD19+ LIC subpopulations were significantly reduced to ≤23.6±21% compared to untreated cells (P≤0.025). The CD34-/CD19- subpopulation demonstrated resistance to Bortezomib with 61.6±28% remaining viable (P=0.144). Encouragingly, all LIC subpopulations responded to Hsp90i treatment (0.1nM Celastrol + 10nM 17-DMAG) with the proportions surviving ranging from 3.0±4% to 10.5±5% compared to untreated cells (P≤0.002). Normal cells were largely unaffected by Bortezomib and Hsp90i (75.9±15% and 90.8±29% surviving, respectively P=0.22). When ALL subpopulations were sorted, treated with Bortezomib then set up in long-term culture, viable cell numbers decreased significantly compared to untreated samples, even in the CD34-/CD19- subpopulation (up to 725-fold from 11.6±16x105 cells to 2.4±1x103, P=0.013). Treatment with Hsp90i also resulted in a significant reduction in viable cells after 4 weeks in culture (up to 161-fold to 8.0±9x103, P=0.015). The ex vivo effects of these drugs on LIC proliferation have also been assessed using NOD/LtSz-scid IL-2Rγc null (NSG) mice. High levels of leukaemia engraftment were observed in NSG with untreated bulk T-ALL cells and LIC subpopulations (60.3%-86.8% leukaemia). Results to date indicate that treatment with Bortezomib, prior to inoculation, prevented engraftment of bulk and all LIC in most cases or suppressed it to only 1.3±2.3% leukaemia cells in 1 NSG inoculated with bulk ALL (P=0.02). Similarly, treatment with Hsp90i prevented engraftment in bulk and LIC subpopulations in 2 of 3 cases. In the third case, a relapse sample, engraftment of some LIC was prevented and significantly reduced in NSG injected with bulk (68.73%), CD34+/CD7+ (24.06%) and CD34-/CD7+ (48.36%) cells (P=0.02). None of the treatment conditions have significantly affected the engrafting capacity of normal HSC (16.21±13.7% with untreated cells, 5.3±9% with Bortezomib P=0.11 and 5.8±7% with Hsp90i P=0.12). In conclusion, proteasome and Hsp90i show promising results in the killing of most LIC in B-ALL and T-ALL and further in vivo studies are warranted to explore their full potential. Disclosures: No relevant conflicts of interest to declare." @default.
• W2287874627 created "2016-06-24" @default.
• W2287874627 creator A5065900158 @default.
• W2287874627 creator A5073611529 @default.
• W2287874627 date "2013-11-15" @default.
• W2287874627 modified "2023-09-27" @default.
• W2287874627 title "Do Proteasome and Heat Shock Protein Inhibitors Eliminate Leukaemia Initiating Cell Populations In Childhood ALL?" @default.
• W2287874627 doi "https://doi.org/10.1182/blood.v122.21.3912.3912" @default.
• W2287874627 hasPublicationYear "2013" @default.
• W2287874627 type Work @default.
• W2287874627 sameAs 2287874627 @default.
• W2287874627 citedByCount "0" @default.
• W2287874627 crossrefType "journal-article" @default.
• W2287874627 hasAuthorship W2287874627A5065900158 @default.
• W2287874627 hasAuthorship W2287874627A5073611529 @default.
• W2287874627 hasConcept C104317684 @default.
• W2287874627 hasConcept C203014093 @default.
• W2287874627 hasConcept C205260736 @default.
• W2287874627 hasConcept C27740335 @default.
• W2287874627 hasConcept C2775932338 @default.
• W2287874627 hasConcept C2776364478 @default.
• W2287874627 hasConcept C2777478702 @default.
• W2287874627 hasConcept C2777560012 @default.
• W2287874627 hasConcept C2778367456 @default.
• W2287874627 hasConcept C28328180 @default.
• W2287874627 hasConcept C502942594 @default.
• W2287874627 hasConcept C54355233 @default.
• W2287874627 hasConcept C71924100 @default.
• W2287874627 hasConcept C86803240 @default.
• W2287874627 hasConcept C95444343 @default.
• W2287874627 hasConceptScore W2287874627C104317684 @default.
• W2287874627 hasConceptScore W2287874627C203014093 @default.
• W2287874627 hasConceptScore W2287874627C205260736 @default.
• W2287874627 hasConceptScore W2287874627C27740335 @default.
• W2287874627 hasConceptScore W2287874627C2775932338 @default.
• W2287874627 hasConceptScore W2287874627C2776364478 @default.
• W2287874627 hasConceptScore W2287874627C2777478702 @default.
• W2287874627 hasConceptScore W2287874627C2777560012 @default.
• W2287874627 hasConceptScore W2287874627C2778367456 @default.
• W2287874627 hasConceptScore W2287874627C28328180 @default.
• W2287874627 hasConceptScore W2287874627C502942594 @default.
• W2287874627 hasConceptScore W2287874627C54355233 @default.
• W2287874627 hasConceptScore W2287874627C71924100 @default.
• W2287874627 hasConceptScore W2287874627C86803240 @default.
• W2287874627 hasConceptScore W2287874627C95444343 @default.
• W2287874627 hasLocation W22878746271 @default.
• W2287874627 hasOpenAccess W2287874627 @default.
• W2287874627 hasPrimaryLocation W22878746271 @default.
• W2287874627 hasRelatedWork W2261122747 @default.
• W2287874627 hasRelatedWork W2518467177 @default.
• W2287874627 hasRelatedWork W2539998088 @default.
• W2287874627 hasRelatedWork W2547940150 @default.
• W2287874627 hasRelatedWork W2552367676 @default.
• W2287874627 hasRelatedWork W2557647391 @default.
• W2287874627 hasRelatedWork W2559199257 @default.
• W2287874627 hasRelatedWork W2570157274 @default.
• W2287874627 hasRelatedWork W2574427153 @default.
• W2287874627 hasRelatedWork W2578639775 @default.
• W2287874627 hasRelatedWork W2584778529 @default.
• W2287874627 hasRelatedWork W2591984724 @default.
• W2287874627 hasRelatedWork W2593277776 @default.
• W2287874627 hasRelatedWork W2594213988 @default.
• W2287874627 hasRelatedWork W2613161302 @default.
• W2287874627 hasRelatedWork W2911800418 @default.
• W2287874627 hasRelatedWork W2913393712 @default.
• W2287874627 hasRelatedWork W2979891175 @default.
• W2287874627 hasRelatedWork W3024948889 @default.
• W2287874627 hasRelatedWork W740184 @default.
• W2287874627 isParatext "false" @default.
• W2287874627 isRetracted "false" @default.
• W2287874627 magId "2287874627" @default.
• W2287874627 workType "article" @default.